And Onyx could receive milestone payments and royalties
from palbociclib, a drug that Pfizer Inc. is studying as a breast cancer treatment.
Not exact matches
► In a news feature in this week's Science, Ken Garber described the surprisingly, frustratingly messy path of
palbociclib, one of the most promising cancer treatments to come along in years,
from its conception in 1995 through its recent, successful phase - II clinical trial.
PALOMA - 1 showed that
palbociclib in combination with the estrogen - production blocker, letrozole, doubled the time it took for metastatic cancer to recur
from a median of 10 months with letrozole plus placebo, to 20 months for
palbociclib plus letrozole.
Cells treated with
palbociclib irreversibly withdraw
from the cell division cycle and enter a state referred to as cellular senescence.